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Abstract
Background—Guidelines suggest that patients with non-dysplastic BE undergo endoscopic
surveillance every 3–5 years, but actual utilization of surveillance endoscopy and the determinants
of variation in surveillance intervals are not known.
Objective—To measure utilization of surveillance endoscopy and its variation in patients with
non-dysplastic BE.
Design—Multi-center, cross-sectional study
Setting—Three sites in Arizona, Minnesota, and North Carolina.
Patients—Participants had prevalent BE without a history of high grade dysplasia or EAC.
Interventions—Participants were given validated measures of quality of life, numeracy, and
cancer risk perception, and the total number of prior endoscopic surveillance exams was
measured.
Main outcome measurements—Over-surveillance was defined as >1 surveillance exam per 3
year period.
Results—Among 235 patients with non-dysplastic BE, 76% were male and 94% Caucasian. The
average duration of BE was 6.5 years (± 5.9 years). The mean number of endoscopies per 3 year
period was 2.7 (± 2.6 years). Over-surveillance was present in 65% of participants, resulting in a
mean of 2.3 excess endoscopies per patient. Neither numeracy skills nor patient perception of
cancer risk were associated with over-surveillance.
Limitations—Endoscopies were measured by patient report, which is subject to error. Results
may only be generalizable to patients seen in academic centers.
Conclusions—Most patients with non-dysplastic BE had more surveillance endoscopic exams
than is recommended by published guidelines. Patient factors did not predict over-surveillance,
indicating that other factors may influence decisions about the interval and frequency of
surveillance exams.
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Introduction
Barrett’s esophagus (BE) is a premalignant condition involving a metaplastic transformation
of the lower esophageal lining from squamous to intestinal epithelium, which is associated
with an increased risk of esophageal adenocarcinoma (EAC) [1, 2]. The risk of EAC in
persons with non-dysplastic BE is roughly 0.5% per year [3–5]. However, this incidence is
30–125 times than that of the general population because EAC is a rare cancer [3, 4].
Despite the increased relative risk of EAC associated with BE, longitudinal studies have
failed to demonstrate increased mortality associated with BE [6, 7].
Endoscopic surveillance of BE with esophagogastroduodenoscopy (EGD) is controversial
due to lack of evidence that BE is linked to increased mortality, and the lack of proven
benefit of surveillance programs. Nevertheless, based on the theory that treatment of
intermediate dysplastic lesions halts the progression to EAC and offers the potential to
mitigate the risk of EAC, guidelines suggest that patients with BE should undergo periodic
endoscopic surveillance, typically once every 3–5 years following initial diagnosis, if no
dysplasia is present [8–13].
There is a gap in the published literature regarding how endoscopic surveillance is practiced
in patients with BE, and how such guidelines are adhered to in practice. The few studies that
have been published on this topic are primarily from physician surveys of practice patterns
[14–19], which do not necessarily represent the patient experience. To that end, we sought to
measure endoscopic utilization in a large population of nondysplastic BE patients from
multiple geographic sites and practice settings. In addition, we aimed to identify predictors
of over or under-utilization of endoscopic surveillance including demographic factors,
quality of life, healthcare numeracy, risk perception, and other health behaviors.
Methods
Study design and setting
This was a multi-center, cross-sectional study of patients with non-dysplastic Barrett’s
esophagus. Participants were recruited from outpatient gastroenterology and endoscopy
clinics at sites in Arizona (Southern Arizona Veterans Administration Medical Center
(SAVAMC), Tucson, AZ), Minnesota (Mayo Clinic, Rochester, MN) and North Carolina
(University of North Carolina (UNC) Hospitals, Chapel Hill, NC). Because all sites are
tertiary referral centers, patients recruited for this study did not necessarily have their BE
diagnosis or endoscopic surveillance at the site at which they were recruited. This study was
approved by each site’s institutional review boards. The coordinating site was the Center for
Esophageal Diseases and Swallowing at UNC, and the central data repository was located
within the Center for Gastrointestinal Biology and Disease at UNC.
Participants
Eligible participants were aged 18–80 and able to read and understand both the consent form
and study surveys. For inclusion, participants had to have prevalent BE for greater than 6
months with either no dysplasia or a single past transient reading of low grade dysplasia
(LGD). BE was defined as any endoscopically detectable upward displacement of the
squamocolumnar junction in to the tubular esophagus of greater than 5mm, with at least one
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biopsy specimen from the area demonstrating specialized columnar epithelium with goblet
cells on routine pathology specimens. Subjects with goblet cells on biopsy, but no
endoscopic appearance of BE, were not eligible for inclusion. Transient LGD was defined as
a reading of LGD on a single biopsy specimen, with at least 1 subsequent endoscopy
negative for dysplasia. Participants were excluded if they had a history of high grade
dysplasia (HGD) or EAC, endoscopic ablation of BE, esophageal resection, or an active
malignancy (except non-melanoma skin cancer). It was the practice of all three sites to
maintain all subjects with prevalent BE on proton pump inhibitor therapy. Subjects were
enrolled from October 2003 through April 2009. All participants provided written informed
consent prior to participation.
Study data
Patients were given a survey to collect demographic information, and other study data
including use of the internet for health information, duration of BE, and number of visits to
healthcare providers per year. Participants were also given a measure of disease-specific
quality of life (GERD-HRQL [20]), a measure of generic quality of life (SF-36 [21]), a
validated eight-item numeracy scale to assess their ability to understand discussions of
numerical risks [22](Supplementary Table A), and a previously-validated risk perception
tool to measure patients’ estimates of their one-year risk of EAC [23] (Supplementary
Figure A). A 1 year risk of EAC of 0.5 – 1% per year was used as the standard risk estimate.
Participants were also asked how often they worry about BE (based on a 5 point Likert
scale, where 1=”not at all” and 5=”almost all the time”), and about their current severity of
heartburn (assessed with a 5 point Likert scale where 1=“no heartburn” and 5=“really bad
heartburn”).
Measurement of endoscopic utilization
Participants were asked the number of times and dates they underwent surveillance
endoscopies. Since patients with a history of endoscopic ablation were excluded, all post-
diagnosis endoscopies were presumed to be for surveillance purposes. To ensure a focus on
surveillance endoscopic exams, only participants with BE for at least 6 months were
included in the utilization analysis. For bivariate and multivariate analysis, over-surveillance
was defined as >1 EGD per 3 year period. We allowed and did not count a single
confirmatory endoscopy within 1 year of the initial BE diagnosis. Excess endoscopies were
calculated using the following formula:
.
Statistical analysis
Sample size calculations were performed based on preliminary data. Previous data
demonstrated that 63% of patients with nondysplastic BE overestimated their 1 year risk of
esophageal cancer, and overestimators underwent an average of 0.14 additional surveillance
endoscopies per year compared to non-overestimators, with a standard deviation of 0.3
endoscopies for both groups [24]. In order to detect if the patient’s perception of cancer risk
was associated with the number of endoscopies they underwent (at an alpha of 0.05 and with
80% power), we estimated that we would need to enroll 100 over-estimators and 58 non-
over-estimators. To allow for variability in the mixture of over-estimators and non-
overestimators of risk by site, as well as to compensate for any decrement in the effect size
noted in our preliminary data, we planned to enroll a total of 240 patients (80 per site).
Exploratory data analysis was performed to examine the distribution of continuous and
categorical values, and to determine missing or implausible values. Bivariate analysis was
then performed to identify variables associated with over utilization of endoscopic
surveillance, using Student’s t-tests for continuous variables, and Pearson’s Chi-squared
Crockett et al. Page 3













tests or Fisher’s exact tests for categorical variables. Multivariate logistic regression
modeling was then performed to estimate odds ratios (OR) and 95% confidence intervals
(95% CI) for factors independently associated with over-surveillance, including non-
collinear variables significantly related to the outcome in bivariate analyses using p value of
≤0.10, and limiting the model to M/10 components (beta coefficients + intercept), where
M=[3*(n1)(n2)]/n (where n1 and n2 are the number of subjects in each group, and n is the
total number of subjects). Covariates in the model included study site, insurance status,
duration of BE, heartburn severity, physician visits per year, and use of internet for
information on BE. Subjects with missing data on the dependent or independent variables
were excluded. A p value of <0.05 and 95% CI that did not include the null value were
considered statistically significant unless otherwise indicated. All statistical analyses were
performed using STATA, version 10.1 (College Station, TX, USA).
Results
Participants
Demographic information is shown in Table 1. A total of 236 patients were recruited, but 1
participant dropped out before completing the study questionnaire, and thus excluded from
the analysis. Overall, 76% were male and 94% Caucasian. Mean age was 62 (± 11.5). Most
patients were well-educated, with 95% reporting at least a high school degree. Roughly
1/3rd of patients came from each site. The mean duration of BE was 6.5 years (± 5.9);
approximately half had BE for 5 or more years.
Endoscopic surveillance utilization
Amongst the194 participants with data on endoscopic surveillance, there were a total of 785
surveillance endoscopies performed. Use of endoscopic surveillance is shown in Table 2,
stratified by site. On average, participants had a surveillance endoscopy every 20.2 months
following their BE diagnosis. Using published guidelines as benchmarks [8–12], patients
had substantially more surveillance endoscopies than even the most aggressive guidelines,
with 1.8 endoscopies per 2 year period. Using a cutoff of >1 endoscopy per 3 year period
(excluding a single confirmatory endoscopy), 65% of all participants experienced excess
endoscopic surveillance (Figure 1). When a more conservative cutoff of >1 endoscopy per 2
year period was used (again excluding a single confirmatory endoscopy), 45% of
participants exceeded the recommended surveillance interval. Even after excluding those
reporting transient LGD in the past (which may have led to increased frequency of
surveillance examinations), most participants (57%) still experienced over-surveillance (>1
per 3 year interval). All told, there was an excess of 233 surveillance exams among the 102
BE patients who were over-surveyed, yielding a mean number of excess endoscopies of 2.3
per patient throughout the duration of their BE diagnosis.
Bivariate and multivariate analyses
Bivariate analysis of factors associated with over-surveillance is shown in Table 3. Although
all sites demonstrated significant rates of over-surveillance, over-surveillance did
significantly vary by site, with UNC having the highest proportion of over-surveillance
compared to Mayo and SAVAMC (40% vs. 30% and 29% respectively, p=0.005). Patients
with private insurance were more likely to experience over-surveillance than either
Medicare or VA populations (53% vs. 22% and 23%, respectively, p=0.04). Those with
over-surveillance generally had BE for fewer years compared to those without over-
surveillance, but this was not statistically significant (6.1 years vs. 7.7 years, p=0.1). Use of
the internet for information on BE was more common in those with over-surveillance vs.
those without, but this did not reach statistical significance in our sample (67% vs. 52%
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respectively, p=0.07). There was no significant difference between groups with respect to
cancer risk perception or numeracy.
Results of multivariate analysis are shown in Table 4. While there were trends towards
increased odds of over-surveillance associated with having private insurance and using the
internet for BE information, none of the examined factors were significantly associated with
over-surveillance. A subgroup analysis of subjects from non-VA sites only (i.e. UNC and
Mayo) revealed similar results (Supplementary Table B).
Discussion
In this multi-center study, we found that endoscopy in the setting of non-dysplastic Barrett’s
esophagus was overutilized. Oversurveyed BE patients had on average 2 excess endoscopies
over the duration of their BE. A rigorous assessment of patient-related variables did not
identify any demographic factors, health behaviors, numeracy skills, quality of life
indicators, or symptom severity measures that predicted over-surveillance in multivariate
analysis.
The health belief model [25] is a social cognitive model that has been developed to help
explain health behaviors. This model suggests that four basic elements underlie and explain
health behavior, including perceived risk, severity, benefits, and barriers. It is within this
context that we measured certain health behaviors and attitudes that could predispose to
over-surveillance, including cancer risk perception and numeracy, quality of life and
symptom severity, and healthcare utilization. Unfortunately, the lack of a strong association
of any of the patient characteristics with over-surveillance argues that interventions directed
towards patients may not be effective in counteracting this phenomenon.
Screening for and surveillance of BE are controversial topics given the rarity of EAC, and
the fact that neither screening nor surveillance have proven to reduce disease-specific or
overall mortality [6, 7, 26]. Nevertheless, guidelines generally recommend that patients with
nondysplastic BE undergo endoscopic surveillance at regular intervals (i.e. every 3–5 years
following diagnosis). Up to 90% of BE patients have non-dysplastic disease [27], so the
patients in this study represent the majority of those with BE who are enrolled in
surveillance programs. Given that the cancer risk is lowest in those with non-dysplastic
disease, endoscopic surveillance in general would be presumed to be least beneficial in such
patients, and, given the large numbers of such patients, “over-surveillance” is most
problematic in this setting. Therefore, understanding whether patient factors contribute to
over-surveillance is important.
Few studies have examined this issue, and studies that have been published on this topic are
predominantly physician surveys focused on provider attitudes and understanding or
adherence to guidelines. Our data are in agreement with previous physician surveys
reflecting the desire for frequent endoscopic surveillance on the part of caregivers. In a
survey of 434 US gastroenterologists performed in 2000, Falk et al. reported that most
respondents recommended a surveillance interval of 2 years for those with no dysplasia
(64%), while 24% recommended more frequent (annual) surveillance exams [15]. In a
survey of 154 gastroenterologists in 2001, Cruz-Correa et al. reported that 65% of
respondents recommended a surveillance interval of 18–24 months for those with non-
dysplastic BE, while 28% recommended a surveillance interval of 7–12 months. Only 5% of
respondents recommended a surveillance interval of 3 years for this group [14]. Surveys of
physicians in Canada [16], Ireland [17], Scotland [18], and the Netherlands [19] reveal
similar results, with wide variation in practice patterns and generally poor reported
adherence to published guidelines. To our knowledge, this is the first published study to
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measure whether patient factors may be associated with increased frequency of endoscopic
surveillance in BE.
We found evidence in bivariate analyses that patients’ insurance status and site of care may
contribute to frequency of endoscopic surveillance. Endoscopic surveillance in the single
payer VA system most closely adhered to published guidelines. We also found that having
private insurance was associated with over-surveillance. The reasons for such associations
may be related to medico-legal concerns, reimbursement issues, or other provider factors. A
2002 survey of 103 Californian gastroenterologists found that up to 30% of respondents
performed surveillance endoscopy despite believing it was neither efficacious or cost-
effective, citing medicolegal concerns as a chief reason for this practice, in addition to
procedure reimbursement and patient preference [28]. In another survey of US
gastroenterologists in 2008, Rubenstein et al. found that physicians who were prior
defendants in malpractice suits recommended more frequent endoscopic surveillance [29].
Taken together, these results suggest that over-surveillance may be more common in
privately-insured patients and that the endoscopist’s fear of liability due to missing dysplasia
or cancer may play an important role in dictating frequency of surveillance. Similar to
previous work [24], a large proportion of patients in this study over-estimated their risk of
cancer; however this over-estimation of risk was not significantly associated with over-
surveillance.
Our findings parallel those of recent studies measuring overutilization of other
gastroenterological procedures. In a study of over 3600 participants enrolled in a colorectal
cancer screening trial, Schoen et al. found that overuse of surveillance colonoscopy was
common: among subjects with an initial negative screening exam, 26.5% underwent a
second surveillance colonoscopy within 5 years despite the fact that a 10 year interval is
generally recommended in this setting [30]. In a study of utilization of upper endoscopy for
gastric ulcers in the US, Saini et al. found that 25% of ambulatory patients with gastric ulcer
had “surveillance EGDs” within 3 months of the index endoscopy (presumably to document
ulcer healing), despite the fact that this practice has not been shown to improve outcomes
and is not generally recommended [31]. In addition, wide variation in practice patterns and
guideline adherence has been described in inflammatory bowel disease [32–34], liver
disease [35, 36], and colorectal cancer screening practices [37, 38] in the US. Our study
provides further evidence that within the field of gastroenterology, there exists variation in
care, with some patients getting too much. Reduction in such variation towards more
consistent evidence-based and guideline-directed practices is a key prerequisite to achieving
better and more cost-effective healthcare [39–41].
This was a multi-center study which measured the surveillance experience of a large number
of non-dysplastic BE patients. The study sites represented 3 different settings of practice
including a public hospital (UNC), a private hospital (Mayo Clinic) and a VA facility
(SAVAMC), which improves the generalizability of our results. However, since all 3 sites
are academic medical centers, these findings may not be representative of community
practice. Our sample contained relatively few patients with low household incomes and/or
no insurance, so our results may not be generalizable to these populations. However, since
BE is more common in higher socioeconomic strata [42], our study subjects are likely a
reasonable representation of the typical Barrett’s population. We used a structured
questionnaire and validated measurement tools for data collection. We evaluated a robust
number of potentially important patient factors as possible contributors to overutilization of
endoscopic surveillance including demographic factors, health behaviors, quality of life
measures, numeracy skills, and risk perception.
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We acknowledge that decisions about endoscopic surveillance are complex. Additionally,
some EGDs that we labeled as “over-surveillance” may have been done for other clinical
reasons, and not solely motivated by cancer prevention. These patients might be expected to
suffer from an increased amount of reflux symptoms compared to the general population. It
is unlikely, however, that symptom-driven investigations account for the marked excess of
endoscopies seen in this study, given that we compared the reported symptom severity in
patients with excess endoscopy to those with appropriate surveillance and did not find
increased reflux symptoms in those with excess endoscopy. Nevertheless, our findings
suggest that overutilization is quite common, and does not seem to be strongly related to any
of the numerous patient factors we measured. There are certain patient factors that we did
not measure that are potentially important, however, such as use of acid-suppression
medication and length of Barrett’s segment.
Endoscopic exams were measured by patient report for several reasons. Firstly, previous
work by our group and others has validated that self report is highly correlated with actual
examinations with a sensitivity of 90% or higher for identifying performed endoscopies [24,
43, 44]. Secondly, this study involved 3 study sites that are tertiary referral centers and thus
the reported endoscopic exams for many of the patients occurred at different institutions
than that of the study site. For this reason, ascertainment by medical records at each study
site would not have captured all surveillance exams. Thirdly, while self report may be
subject to misreporting, there is no reason to suspect that over-reporting would be more
common than under-reporting. Lastly, even if there was some over-reporting of surveillance
endoscopies, it is unlikely that measurement bias would be substantial enough to explain the
>200% surplus of surveillance exams we report. The retrospective design of this study may
have resulted in under-enrollment of those who are surveyed at longer intervals and
underestimation of surveillance intervals. However, a sensitivity analysis artificially
enriching the population with subjects surveyed at longer intervals demonstrated that this
bias is unlikely to nullify our finding of surplus surveillance exams (Supplementary Table
C). Although non-participation was low in this study, information on the exact number of
subjects who declined participation and reasons for non-participation is not available,
making detection bias a possibility.
In conclusion, we have found that overutilization of endoscopic surveillance is common in
non-dysplastic BE, even using the most liberal definition for an “indicated” exam. Over-
surveillance does not appear to be related to factors such as age, gender, altered risk
perception, patients’ anxiety, numeracy, quality of life or symptom severity. Private
insurance was associated with an increased likelihood of excess endoscopy. Whether
overutilization of endoscopic surveillance is related to non-patient factors such as
medicolegal concerns or other endoscopist characteristics is a fertile area for future study.
These data also suggest that improved physician adherence to guidelines regarding
endoscopic surveillance of non-dysplastic BE is needed so that healthcare resources can be
better allocated to areas with more proven benefits.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scatter plot of rate of endoscopy per 3 year period by duration of Barrett’s esophagus,
including all participants on whom endoscopy data and Barrett’s duration data were
available who had BE for more than 6 months (n=156), and discounting a single
confirmatory endoscopy after initial BE diagnosis. Dotted line represents the recommended
surveillance interval of the AGA, ACG and ASGE of 1 endoscopy every 3 years.[8, 9, 13]
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Table 1
Characteristics of study participants with Barrett’s esophagus (n=235)
Characteristic n (%)
Sex
 Female 54 (22.9)
 Male 180 (76.3)
Age
 <50 years 35 (15.0)
 50–59 years 56 (23.9)
 60–69 years 76 (32.5)
 70–80 years 67 (28.6)
Race
 Black 5 (2.1)
 White 221 (94.0)
 Other 9 (3.8)
Site
 UNC 81 (34.5)
 SAVAMC 75 (31.9)
 Mayo 79 (33.6)
Education
 < High school graduate 12 (5.2)
 High school graduate 46 (19.9)
 Some college 75 (32.5)
 ≥College graduate 98 (42.4)
Annual household income
 <$25,000/year 26 (17.0)
 $25,000–50,000/year 52 (34.0)
 $50,000–100,000/year 52 (34.0)
 >$100,000/year 23 (15.0)
Employment*
 Employed 109 (47.0)
 Retired 131 (55.7)
Family history
 Barrett’s 23 (10.4)
 Esophageal cancer 13 (5.5)
Insurance†
 No insurance 7 (3.0)
 Medicaid 2 (0.9)
 Private 114 (48.5)
 Medicare 54 (23.0)
 VA 56 (23.8)
Years with Barrett’s Esophagus
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Characteristic n (%)
 <1 year 31 (14.9)
 1–4 years 79 (38.0)
 5–9 years 48 (23.1)
 ≥10 years 50 (24.0)
*
percentages for employment don’t add to 100 due to overlap in categories (e.g. part-time employment following formal retirement)
†
When multiple insurance types listed, hierarchical assignment was private→VA→Medicare→Medicaid→no insurance
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Table 2










Years with BE (mean ± SD) 6.5 ± 5.9 5.2 ± 5.4 9.3 ± 6.2 5.2 ± 5.2
Endoscopy after BE diagnosis
 Yes (n (%)) 211 (92.1) 68 (87.2) 69 (94.5) 74 (94.9)
 No (n (%)) 18 (7.9) 10 (12.8) 4 (5.5) 4 (5.1)
Total surveillance endoscopies (mean ± SD) 4.0 ± 4.0 3.1 ± 2.8 5.3 ± 5.1 3.8 ± 3.7
Months per endoscopy (mean ± SD) 20.2 ± 16.8 20.9 ± 18.6 25.4 ± 14.2 14.3 ± 15.5
Surveillance endoscopies per 2 year period† (mean ± SD) 1.8 ± 1.7 1.5 ± 1.0 1.1 ± 0.7 2.8 ± 2.5
Surveillance endoscopies per 3 year period† (mean ± SD) 2.7 ± 2.6 2.2 ± 1.5 1.7 ± 1.0 4.2 ± 3.7
>1 endoscopic surveillance per 2 year period†‡ (n (%)) 70 (44.9) 20 (37.7) 16 (29.6) 34 (69.4)
>1 endoscopic surveillance per 3 year period†‡ (n (%)) 102 (65.4) 30 (56.6) 31 (57.4) 41 (83.7)
†
Patients with BE<6 months were excluded from these analyses.
‡
Discounting a single confirmatory endoscopy following BE diagnosis
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Table 3
Bivariate analysis comparing those with overutilization of surveillance endoscopy to those without
overutilization.*
Variables
≤1 endoscopy per 3 years
n = 54
n (%) or mean ± SD
>1 endoscopy per 3 years
n = 102
n (%) or mean ± SD p†
Sex 0.6
 Female 10 (18.5) 22 (21.8)
 Male 44 (81.5) 79 (78.2)
Age 62.1 ± 11.5 61.1 ± 11.5 0.6
Race 0.5
 Black 0 (0.0) 2 (2.0)
 White 53 (98.2) 95 (93.1)
 Other 1 (1.8) 5 (4.9)
Site 0.005
 UNC 8 (14.8) 41 (40.2)
 SAVAMC 23 (42.6) 31 (30.4)
 Mayo 23 (42.6) 30 (29.4)
Education 0.3
 < High school graduate 0 (0.0) 5 (5.0)
 High school graduate 12 (22.6) 16 (15.8)
 Some college 20 (37.7) 33 (32.7)
 ≥College graduate 21 (39.6) 47 (46.5)
Annual household income 0.6
 <$25,000/year 8 (17.8) 6 (10.0)
 $25,000–50,000/year 15 (33.3) 24 (40.0)
 $50,000–100,000/year 16 (35.6) 19 (31.7)
 >$100,000/year 6 (13.3) 11 (18.3)
Insurance‡ 0.04
 No insurance 3 (5.6) 2 (2.0)
 Medicaid 1 (1.9) 0 (0.0)
 Private 18 (33.3) 54 (53.5)
 Medicare 12 (22.2) 22 (21.8)
 VA 20 (37.0) 23 (22.8)
Family history of Barrett’s esophagus 7 (13.2) 10 (10.3) 0.6
Family history of esophageal cancer 2 (3.7) 7 (6.9) 0.7
Years with Barrett’s Esophagus 7.7 ± 6.0 6.1 ± 5.5 0.1
GERD HRQL 9.1 ± 8.9 7.8 ± 7.8 0.3
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Variables
≤1 endoscopy per 3 years
n = 54
n (%) or mean ± SD
>1 endoscopy per 3 years
n = 102
n (%) or mean ± SD p†
SF-36
 Physical component summary 44.8 ± 11.1 47.0 ± 10.2 0.2
 Mental component summary 49.8 ± 11.4 50.9 ± 11.6 0.6
Heartburn severity 2.0 ± 1.2 1.8 ± 1.1 0.1
Worry of BE 2.2 ± 1.0 2.1 ± 1.1 0.4
Risk perception§ 0.5
 Overestimator 23 (43.4) 37 (38.1)
 Under/true estimator 30 (56.6) 60 (61.9)
Physician visits/year 1.5 ± 1.7 1.2 ± 0.8 0.1
Dentist visits/year 1.3 ± 0.8 1.3 ± 0.7 0.9
Numeracy score** 87.0% ± 16.5% 84.0% ± 19.9% 0.4
Any use of internet for BE information 28 (51.9) 67 (67.0) 0.07
*
Table includes data on the subset of subjects who had BE for ≥ 6 months, were able to ascertain their date of diagnosis, and could recall their
endoscopy history (n=156). Overutilization defined as >1 endoscopy per 3 years, discounting a single confirmatory EGD.
†
p values obtained via χ2 tests or Fisher’s exact tests for categorical variables, and Student’s t-tests for continuous variables.
‡
When multiple insurance types listed, hierarchical assignment was private→VA→Medicare→Medicaid→no insurance
§
Measured with validated risk perception tool. Overestimators defined as those who estimated their 1 year risk of BE of >1%.
**
Numeracy scores reflect ability of participants to answer 8 simple math questions as part of a validated numeracy measurement tool [22]. The
highest score on this measure is 100%.
GERD HRQL: Gastroesophageal Reflux Disease Health-Related Quality of Life Questionnaire, a measure of disease-targeted quality of life;
SF-36: Medical Outcomes Study Short Form-36, a measure of generic quality of life; BE: Barrett’s esophagus. UNC: University of North Carolina;
SAVAMC: Southern Arizona Veterans Administration Medical Center
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Table 4
Multivariate analysis of factors related to overutilization of endoscopy*
Factor Odds Ratio (95% CI)
Insurance status†
 Private 1.00 (referent)
 Medicare 0.65 (0.25, 1.66)
 VA 0.48 (0.20, 1.13)
 No insurance/Medicaid 0.25 (0.04, 1.61)
Years with Barrett’s esophagus‡ 0.97 (0.91, 1.03)
Heartburn severity§ 0.91 (0.66, 1.24)
Physician visits per year 0.89 (0.66, 1.20)
Use of internet for BE information 1.49 (0.71, 3.12)
*
Overutilization defined as >1 endoscopy per 3 year period, discounting a 1st confirmatory endoscopy, and excluding patients with BE<6 months
†
When multiple insurance types listed, hierarchical assignment was private→VA→Medicare→Medicaid→no insurance. Private insurance was
used as the referent category, as this was the largest group, and no insurance/Medicaid strata were collapsed. Since insurance status and study site
were collinear, both variables were not included in modeling.
‡
OR represents change in odds per 1 year increase in duration of BE
§
Heartburn severity measured by 5 point Likert scale where 0=no heartburn and 5=really bad heartburn
BE: Barrett’s esophagus
Odds ratios obtained via multivariate logistic regression modeling
Gastrointest Endosc. Author manuscript; available in PMC 2014 March 20.
